Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729828 | 0.83 | ADRA1A (0.38) | — | |
| SCHEMBL22729769 | 0.83 | MAPK14 (0.44) | RAB9ASMN1; SMN2TP53KDM4EF2 | |
| SCHEMBL22729488 | 0.80 | KDM4E (0.45) | MEN1KMT2ARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL29839367 | 0.72 | SCN9A (0.43) | MEN1KMT2ARAB9ASMN1; SMN2TP53 | |
| SCHEMBL22729787 | 0.72 | SCN9A (0.43) | MEN1KMT2ARAB9ASMN1; SMN2TP53 | |
| SCHEMBL22729782 | 0.69 | UGCG (0.43) | MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL23139902 | 0.68 | UGCG (0.42) | KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL22729466 | 0.68 | NPBWR1 (0.43) | TP53KDM4EALDH1A1NPBWR1 | |
| SCHEMBL22552364 | 0.63 | DHODH (0.50) | MGLLRAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL22729846 | 0.63 | KDM4E (0.43) | JAK2BTKMGLLL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | MEN1 1745/4885KMT2A 405/4885JAK2 3262/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | MEN1 1710/4885KMT2A 410/4885JAK2 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.